[Modifications of catecholamine metabolism under the effect of a decarboxylase inhibitor associated with L-dopa and desipramine in patients with depressive and parkinsonian syndromes].
D000328:Adult; D000368:Aged; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D002395:Catecholamines / Q000378:metabolism* / Q000652:urine; D003863:Depression / Q000188:drug therapy* / Q000378:metabolism; D003891:Desipramine / Q000627:therapeutic use*; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use*; D004298:Dopamine / Q000652:urine; D004837:Epinephrine / Q000652:urine; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000652:urine; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism; D011868:Radioisotopes
D002395:Catecholamines; D006834:Hydrazines; D011868:Radioisotopes; D004295:Dihydroxyphenylalanine; D002262:Carboxy-Lyases; D003891:Desipramine; D004298:Dopamine; D009638:Norepinephrine; D004837:Epinephrine
Modifications du métabolisme des catecholamines sous l'effet d'un inhibiteur de la décarboxylase associé a la L-dopa et á la désipramine chez des patients atteints de syndromes dépressifs et parkinsoniens.